ºÚÁÏÍø

T-cells; Neuroinflammation; Multiple sclerosis; CD4+ T-helper cells; CD8+ cytotoxic T-cells; Th17 cells; Regulatory T-cells; Immunotherapy

Introduction

Multiple sclerosis (MS) is a complex autoimmune disease of the central nervous system (CNS), which affects millions of individuals worldwide. It is characterized by progressive neuroinflammation, demyelination, axonal injury, and neurodegeneration. The immune system plays a pivotal role in the disease, with T-cells being central mediators of the inflammatory processes that drive MS pathogenesis. Although the precise cause of MS remains unknown, it is clear that immune dysregulation, particularly the aberrant activation of T-cells, is a key factor in disease initiation and progression. Upon activation, autoreactive T-cells infiltrate the CNS, where they release pro-inflammatory cytokines, disrupt the blood-brain barrier (BBB), and induce damage to myelin and axons. The role of T-cells in MS is complex, involving various subsets of helper and cytotoxic T-cells that contribute to the disease in different ways.

Recent advances in understanding the immune mechanisms driving MS have focused on the roles of Th1, Th17, and regulatory T-cells (Tregs) in neuroinflammation. Th1 cells are known for their ability to produce pro-inflammatory cytokines like interferon-gamma (IFN-γ), which directly contribute to neuroinflammation. Th17 cells, characterized by their production of interleukin-17 (IL-17), are also heavily implicated in MS. Additionally, the role of Tregs in modulating immune responses and maintaining immune tolerance has garnered significant attention, as their dysfunction may exacerbate autoimmune responses in MS. This review aims to critically examine the role of T-cells in neuroinflammation, highlighting the mechanisms of action and their contribution to disease pathogenesis [1].

Results

T-cells play an essential role in MS by mediating the neuroinflammatory responses that lead to demyelination and neurodegeneration. The initial stages of MS are marked by the activation of autoreactive T-cells in the periphery, followed by their migration across the blood-brain barrier (BBB) into the CNS. Once within the CNS, these T-cells release a range of pro-inflammatory cytokines that exacerbate the inflammatory response. The most well-characterized T-cell subsets in MS are Th1 and Th17 cells, both of which contribute significantly to the disease's pathology. Th1 cells, known for their production of IFN-γ, are involved in driving macrophage activation and enhancing the inflammatory milieu in the CNS. Th17 cells, on the other hand, secrete IL-17, a cytokine that promotes the recruitment of neutrophils and other immune cells into the CNS, thereby exacerbating neuroinflammation. In addition to these two major T-helper subsets, CD8+ cytotoxic T-cells also play a crucial role in MS. These cells are involved in direct cytotoxic attacks on myelinated neurons and oligodendrocytes, contributing to axonal damage and neuronal loss. Recent studies have also identified tissue-resident memory T-cells (TRM) as key players in MS pathogenesis. TRMs are long-lived immune cells that persist in the CNS and are capable of rapidly responding to reactivation of MS disease in the brain and spinal cord, driving relapses and chronic inflammation [2,3]. Regulatory T-cells (Tregs) are critical for maintaining immune homeostasis and suppressing autoreactive immune responses. In MS, the function of Tregs is often impaired, leading to an unchecked activation of pro-inflammatory T-cells and contributing to the disease process. Tregs act by producing anti-inflammatory cytokines such as IL-10 and transforming growth factor-beta (TGF-β), which suppress the activity of effector T-cells. The loss of Treg function or number has been implicated in the failure to control the aberrant T-cell responses seen in MS, thus promoting the autoimmune response that underlies the disease [4].

Emerging evidence suggests that the interaction between various T-cell subsets and their cytokine profiles plays a key role in determining the severity and progression of MS. For example, while Th1 and Th17 cells are considered the primary pro-inflammatory T-cell subsets in MS, the balance between these cells and Tregs is critical in regulating the inflammatory response. Imbalances that favor Th1 and Th17 responses over Treg activity may lead to exacerbated neuroinflammation and disease progression. This highlights the importance of understanding the complex interactions between these T-cell subsets and their contribution to disease severity [5].

Discussion

The role of T-cells in the pathogenesis of MS is multifaceted, involving multiple subsets of T-cells with distinct roles in the inflammatory process. Th1 and Th17 cells are central to the initiation and progression of the disease, driving neuroinflammation through the production of pro-inflammatory cytokines. However, the role of CD8+ cytotoxic T-cells, which directly attack myelin and axons, underscores the broader immune dysfunction in MS. The emerging understanding of tissue-resident memory T-cells provides insight into the chronicity and relapse mechanisms of MS, as these cells can rapidly reinitiate inflammation upon reactivation. In contrast, Tregs play an essential role in regulating these immune responses and maintaining immune tolerance. The dysregulation of Treg function in MS, as well as the failure to suppress autoreactive T-cell responses, contributes to the disease’s chronic inflammatory state.

Therapeutic strategies targeting T-cell mediated neuroinflammation are actively being pursued, with several promising approaches under investigation. One major area of focus has been the development of drugs that can modulate T-cell activation and migration. For example, sphingosine-1-phosphate receptor (S1PR) modulators, such as fingolimod, have been shown to reduce T-cell trafficking into the CNS and decrease inflammation. Other strategies aim to selectively target Th1 and Th17 responses, such as the use of monoclonal antibodies against IL-17 or its receptor, which have demonstrated efficacy in reducing disease activity in MS patients. Furthermore, therapies aimed at enhancing Treg function, either by expanding Treg populations or by enhancing their suppressive activity, may hold promise for restoring immune tolerance and preventing disease progression. However, despite these advances, challenges remain in identifying therapies that are both effective and safe for long-term use. The need for precision medicine in MS is clear, as treatments must be tailored to the individual patient’s immune profile and disease course [6,7].

Recent advancements in understanding the molecular mechanisms driving T-cell activation, migration, and persistence in the CNS have opened new avenues for therapeutic intervention. However, translating these findings into clinically effective therapies remains a challenge. The complex network of cytokine interactions, T-cell subsets, and the blood-brain barrier must be carefully considered in the design of new treatments. Additionally, while targeting T-cell responses offers significant potential, careful consideration must be given to the risk of immunosuppression and its associated complications, such as increased susceptibility to infections [8-10].

Conclusion

T-cell mediated neuroinflammation is a central feature of MS, with CD4+ Th1 and Th17 cells, CD8+ cytotoxic T-cells, and regulatory T-cells playing key roles in disease pathogenesis. The imbalance between pro-inflammatory T-cell responses and immune regulatory mechanisms contributes to the chronic inflammatory state observed in MS. The emerging understanding of T-cell subsets and their roles in MS has led to the development of targeted therapies aimed at modulating these immune responses. While promising, these therapies must be carefully evaluated for long-term safety and efficacy. Ongoing research into the molecular pathways governing T-cell activation and migration, along with the development of precision medicine approaches, will be crucial for improving the management and outcomes of MS patients. Continued efforts to better understand the complex immunological landscape of MS are vital for advancing therapeutic strategies and ultimately offering better disease-modifying treatments for MS patients.

1. de Bruijn MA, Bruijstens AL, Bastiaansen AEM, van Sonderen A, Schreurs MW, et al. (2020)  . Neurol Neuroimmunol Neuroinflamm 7(3):e682.

, ,

2. Hughes EG, Peng X, Gleichman AJ, Lai M, Zhou L, et al. (2010) . J Neurosci 30:5866-5875.

, ,

3. Patel A, Meng Y, Najjar A, Lado F, Najjar S (2022) Autoimmune Encephalitis: . Brain Sci 12(9):1130.

, ,

4. Cohen D, Nicolas JD, Flament MF, Périsse D, Dubos PF, et al. (2005) . Schizophrenia Research. 76:301-308.

ÌýÌýÌýÌýÌýÌý , ,

5. Thakur A, Jagadheesan K, Dutta S, Sinha VK (2003) . Aust NZJ Psychiatry 37(2):200-203.

, ,

6. Consoli A, Raffin M, Laurent C, Bodeau N, Campion D, et al. (2012)  . Schizophr Res 137(1-3):151-8.

, ,

7. Cornic F, Consoli A, Tanguy ML, Bonnot O, Périsse D, et al. (2009) . Schizophrenia Research.113(2–3):233-40.

, ,

8. Cellucci T, Van Mater H, Graus F, Muscal E, Gallentine W, Klein-Gitelman MS, et al. (2020) . Neurol Neuroimmunol Neuroinflamm.7(2):e663.

ÌýÌýÌýÌýÌýÌý , ,

9. Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, et al.(2016) . The Lancet Neurology 15(4):391-404.

, ,

10. American Psychiatric Association, American Psychiatric Association (2013). . Washington D.C: American Psychiatric Association 947 p.

ÌýÌýÌýÌýÌýÌý